Immunotherapy for recurrent glioblastoma: practical insights and challenging prospects

by Xin Wang, Jie Lu, Gaochao Guo, Jinming Yu
Published 2021-03-01

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

by Xin Wang, Gaochao Guo, Hui Guan, Yang Yu, Jie Lu, Jinming Yu
Published 2019-02-01

CYT387, a potent IKBKE inhibitor, suppresses human glioblastoma progression by activating the Hippo pathway

by Xin Wang, Jie Lu, Jing Li, Yang Liu, Gaochao Guo, Qiang Huang
Published 2021-09-01

IKBKE promotes glioblastoma progression by establishing the regulatory feedback loop of IKBKE/YAP1/miR-Let-7b/i

by Zhimeng Zhang, Jie Lu, Gaochao Guo, Yi Yang, Shicai Dong, Yang Liu, Yang Nan, Yue Zhong, Kai Yu, Qiang Huang
Published 2017-07-01

IKBKE, a prognostic factor preferentially expressed in mesenchymal glioblastoma, modulates tumoral immunosuppression through the STAT3/PD‐L1 pathway

by Li Yi, Gaochao Guo, Jiabo Li, Xiaoguang Fan, Tao Li, Luqing Tong, Peidong Liu, Xuya Wang, Feng Yuan, Shengping Yu, Qiang Huang, Xuejun Yang
Published 2020-07-01

LncRNA HAS2-AS1 Promotes Glioblastoma Proliferation by Sponging miR-137

by Yalin Lu, Yalin Lu, Yalin Lu, Gaochao Guo, Rujun Hong, Rujun Hong, Rujun Hong, Xingjie Chen, Xingjie Chen, Xingjie Chen, Yan Sun, Yan Sun, Yan Sun, Fang Liu, Zhimeng Zhang, Xun Jin, Xun Jin, Xun Jin, Xun Jin, Jun Dong, Kai Yu, Kai Yu, Kai Yu, Xuejun Yang, Xuejun Yang, Xuejun Yang, Yang Nan, Yang Nan, Yang Nan, Yang Nan, Qiang Huang, Qiang Huang, Qiang Huang, Qiang Huang
Published 2021-05-01